Home > Insider Trading > Filing (0001144204-18-002932)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
850261	Sorrento Therapeutics Inc.	SRNE	Services-Commercial Physical & Biological Research (8731)	330344842

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1470981	Henry Ji	C/O Sorrento Therapeutics, Inc. 4955 Directors Place San Diego CA 92121	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-01-21	1,801,801	$0.00	1,841,577	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant (right to buy)	Acquisiton	2018-01-21	261,438	$0.00	261,438	$8.50

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
261,438	2016-06-07	2019-06-07	No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	135,863	Indirect	See Footnote
Common Stock	29,001	Indirect	By spouse
Common Stock	2,153,162	Indirect	See Footnote

Footnotes

On January 21, 2018, the Reporting Person entered into a Securities Purchase Agreement (the "SPA") with a third party whereby the Reporting Person agreed to purchase from the third party, and the third party agreed to sell to the Reporting Person, an aggregate of 1,801,801 shares of the Issuer's common stock (the "Shares") and a warrant to purchase an aggregate of 261,438 shares of the Issuer's common stock (the "Warrant"). The closing of the purchase and sale of the Shares and the Warrant as contemplated by the SPA has not yet occurred, but is expected to close no later than February 19, 2018. As the closing of the purchase and sale of the Shares and the Warrant is not subject to satisfaction of material conditions beyond the control of the parties, the Reporting Person is reporting the purchase of the Shares and the Warrant at this time.
The aggregate purchase price for the Shares and the Warrant pursuant to the SPA is $11,531,526.40.
Shares are held by an entity of which the Reporting Person and his spouse are the sole members and managing directors.
Shares are held in a family trust of which the Reporting Person is a co-trustee with his wife.